Pediatrix Medical Group, Inc. (MD) Stock Price & Analysis
Pediatrix Medical Group, Inc. (MD) closed at USD 29.55 on Thursday, October 22, 2026, up 5.16% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 29.55; the Oct 22, 2026 session ranged USD 28.11–29.68 on volume of 1,087,718 shares. Market capitalization is —, with a 52-week range of USD 16.89–29.69 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:01 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MD.md
Key facts (MD)
- Last four reported quarters (through Jun 30, 2026): revenue $1.95B, net income $175M (9.0% margin) (SEC filings).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $856K; 1 not under a Rule 10b5-1 plan ($856K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.86 on a 1–5 scale) (7 analysts), mean target USD 26.33 (range 21–28).
- Total return with dividends: 1Y +72.1% vs S&P 500 +14.9%; 5Y +9.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 0.65, revenue estimate $498M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.91B | $1.97B | $1.99B | $2.01B | $1.91B | $1.95B |
| Operating income | $203M | $173M | $7.3M | -$68.7M | $209M | $215M |
| Net income | $131M | $66.3M | -$60.4M | -$99.1M | $165M | $175M |
| EPS (diluted) | $1.53 | $0.79 | -$0.73 | -$1.19 | $1.94 | — |
| Operating margin | 10.6% | 8.8% | 0.4% | -3.4% | 10.9% | 11.0% |
| Net margin | 6.9% | 3.4% | -3.0% | -4.9% | 8.6% | 9.0% |
| Revenue growth | +10.2% | +3.2% | +1.1% | +0.9% | -4.9% | — |
| Cash + short-term investments | $487M | $103M | $178M | $349M | $500M | — |
| Total debt | $990M | $637M | $622M | $611M | $571M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MD)
P/E at fiscal year-ends: Dec 2025 11.0x.
Insider sales (SEC Form 4, open-market, last ~7 months) (MD)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-13 | Weis Shirley A | Director | 36,028 | $856K | 65.9% | No | Too little history (no open-market trades in 2024 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (MD)
Consensus Hold (mean 2.86 on a 1–5 scale), 7 analysts; mean target USD 26.33 (low 21, high 28).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | Jefferies | Downgrade | Buy → Hold | $27 → $28 |
| 2026-08-06 | UBS | Target raised | Neutral | $25 → $28 |
| 2026-07-14 | Truist Securities | Target raised | Hold | $23 → $28 |
Total return (dividends reinvested) (MD)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +72.1% | +9.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +72.4% | +1.8% |
| Volatility (annualized) | 41.1% | 42.3% |
| Max drawdown | -23.6% (Nov 2025→Feb 2026) | -76.3% (Nov 2021→Jul 2024) |
MD revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Health Care Patient Service | $418.7M | 85.8% | +5.4% |
| Hospitals Contracts | $68.3M | 14.0% | +0.1% |
| Product & Service Other | $779,000 | 0.2% | -75.7% |
| Total revenue | $487.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MD company outlook (results filed Aug 4, 2026)
- “A reconciliation of projected full year 2026 Adjusted EBITDA to the most directly comparable GAAP financial measures is also provided in the financial tables of this press release.”
Quoted word-for-word from the SEC 8-K results press release.
MD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.65 | $0.67 | -2.7% | $498.2M | 7 |
| Next quarter (ends Dec 2026) | $0.63 | $0.58 | +8.0% | $499.1M | 7 |
| Current fiscal year (ends Dec 2026) | $2.35 | $2.28 | +3.2% | $1.96B | 7 |
| Next fiscal year (ends Dec 2027) | $2.44 | $2.36 | +3.5% | $2.01B | 6 |
Key Statistics (as of October 23, 2026 at 10:01 UTC)
| Price | USD 29.55 |
|---|---|
| Change | ▲ 5.16% (up) |
| Previous Close | USD 29.55 |
| Open | USD 29.55 |
| Day Range | USD 28.11 – 29.68 |
| 52-Week Range | USD 16.89 – 29.69 |
| Volume | 1,087,718 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (MD)
Nexqual's technical model rates MD "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 10:01 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 73.17 (overbought) |
| vs SMA50 | Above (USD 26.6) |
| MACD | 0.57 (positive) |
Analyst Ratings (MD)
Wall Street analysts rate MD "Hold" based on 7 analysts, with a mean price target of USD 26.33 (range USD 21–28), per Nexqual as of October 23, 2026 at 10:01 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 26.33 |
| High Target | USD 28 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 1 / 6 / 0 |
Earnings (MD)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.65 |
| Revenue Estimate | $498.18M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.63 vs est 0.59 ▲ beat |
| 2026-03-31 | USD 0.44 vs est 0.38 ▲ beat |
| 2025-12-31 | USD 0.5 vs est 0.54 ▼ miss |
| 2025-09-30 | USD 0.67 vs est 0.47 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financials & Fundamentals (MD)
| Total Revenue | $1.95B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.00% |
| Gross Margin | +26.24% |
| Operating Margin | +13.41% |
| Profit Margin | +8.96% |
| ROE | +20.39% |
| Debt / Equity | 0.7 |
| Current Ratio | 1.32 |
| Total Cash | $404.20M |
| Total Debt | $619.96M |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Ownership (MD)
| Insider Ownership | +2.03% |
|---|---|
| Institutional Ownership | +106.98% |
| Shares Outstanding | 81.25M |
| Float | 77.99M |
| Short % of Float | +8.09% |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
From Pediatrix Medical Group, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed significant administrative expertise relating to our practice physician services.
- Analysis of the data within our clinical data warehouses across our neonatology and other pediatric subspecialty services allows us to provide feedback to our physicians and hospital partners and to develop and implement best practices, all with the goal of improving outcomes, creating efficiencies and ensuring patient satisfaction.
- We believe that these initiatives have been enhanced by our integrated national presence together with our clinical and management information systems, which are an integral component of our clinical research and education activities.
- We maintain systems that provide for electronic data interchange with payors that accept electronic submissions, including electronic claims submission, insurance benefits verification and claims processing and remittance advice, which enable us to track numerous and diverse third-party payor relationships and payment methods.
Partnerships
- In most of our affiliated practice groups, each physician has entered into an employment agreement with us or one of our affiliated professional contractors providing for a base salary and incentive bonus eligibility and typically having a term of three to five years.
- Each of our affiliated professional contractors has entered into a comprehensive management agreement with a subsidiary of Pediatrix as the manager.
Legal & Regulatory Risks (Item 1A, quoted)
- We could be affected by potential changes to healthcare laws, rules and regulations, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion and contraction.
- The Medicare Access and CHIP Reauthorization Act of 2015 ("MACRA") and potential changes to it may have an adverse effect on our business.
- The Transparency in Coverage Final Rule, which requires certain health plans and issuers to publish pricing information on in-network and out-of-network providers and make price comparison and cost-sharing information available to insureds, could have a material impact on our business.
- Expanding eligibility of GHC Programs could adversely affect our reimbursement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACHC | Acadia Healthcare Company, Inc. | USD 31.88 | ▲ 1.43% |
| USPH | U.S. Physical Therapy, Inc. | USD 88.73 | ▲ 2.84% |
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
| PBH | Prestige Consumer Healthcare In | USD 49.46 | ▲ 3.21% |
| EHC | Encompass Health Corporation | USD 126.01 | ▲ 4.6% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:01 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt